Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: polyethylene Clear all
Completed Phase 4 Interventional Results available

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

NCT03317795
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions
Levonorgestrel IUS, Tranexamic Acid
Drug
Lead sponsor
Shannon K. Laughlin-Tommaso
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use

NCT01143259
View directory record Official record
Conditions
Ileus
Interventions
Alvimopam, 300 mg Polyethylene
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
American Fork, Utah • Cedar City, Utah • Logan, Utah + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

NCT06028438
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo, Nipocalimab, Certolizumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Huntington Beach, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Morning-Only 4 L PEG vs Split Dose Prep for Afternoon Colonoscopies, Endoscopist-Blinded Prospective Study

NCT02643316
View directory record Official record
Conditions
Colonoscopy
Interventions
Same day 4 L preparation (Polyethylene Glycol), Split dose 4 L preparation (Polyethylene Glycol)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of PEG-400 and Systane Artificial Tears (Alcon) on Quality of Vision

NCT00627302
View directory record Official record
Conditions
Myopia
Interventions
PEG-400, Systane
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Rockville Centre, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2008 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Pre-operative Polyethylene Glycol 3350 for Minimally Invasive Urogynecologic Surgery

NCT06159777
View directory record Official record
Conditions
Constipation, Surgical Procedure, Unspecified, Prolapse; Female
Interventions
Polyethylene Glycol 3350
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy

NCT01170754
View directory record Official record
Conditions
Colon Cancer
Interventions
PEG-3350 and Gatorade, Golytely 4 liters
Drug
Lead sponsor
Temple University
Other
Eligibility
40 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 27, 2026, 10:27 PM EDT
Withdrawn Not applicable Interventional

Anatomic Versus Reverse Shoulder Arthroplasty for Primary Glenohumeral Osteoarthritis

NCT06513559
View directory record Official record
Conditions
Glenohumeral Osteoarthritis
Interventions
Anatomic total shoulder replacement, Reverse total shoulder replacement
Device
Lead sponsor
University of Utah
Other
Eligibility
60 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

NCT00160706
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol (CDP870)
Biological
Lead sponsor
UCB Pharma SA
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 27, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

NCT03170232
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 76 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 3 Interventional Results available

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

NCT03357471
View directory record Official record
Conditions
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions
e-Device
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Sep 27, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional Results available

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT02419469
View directory record Official record
Conditions
Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
Interventions
Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 27, 2026, 10:27 PM EDT
Terminated Phase 4 Interventional Results available

Comparison of Potassium Binders in the ER

NCT04585542
View directory record Official record
Conditions
Acute Hyperkalemia, Oral Potassium Binders
Interventions
Polyethylene Glycol 3350, Sodium Polystyrene Sulfonate Oral Suspension [SPS], Patiromer, Sodium zirconium cyclosilicate
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

NCT01147341
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Cimzia, Placebo
Drug
Lead sponsor
Michael Schiff, MD
Individual
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.

NCT04534465
View directory record Official record
Conditions
Constipation
Interventions
Polyethylene glycol (MiraLAX, BAY81-8430), Mannitol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for Toxicity Evaluation of HIV Rectal Microbicides

NCT00389311
View directory record Official record
Conditions
HIV Infections
Interventions
Normosol-R, Nonoxynol-9, Gastrointestinal instrumentation
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

NCT02481219
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin
Device · Drug
Lead sponsor
Medtronic - MITG
Industry
Eligibility
50 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

36 mm Ceramic-on-Ceramic Acetabular Cup Total Hip Replacement

NCT00953719
View directory record Official record
Conditions
Non-inflammatory Degenerative Joint Disease
Interventions
36 mm ceramic head on a ceramic acetabular liner, 28 mm ceramic head on a polyethylene acetabular liner
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
20 Years to 75 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
5
States / cities
Sacramento, California • Denver, Colorado • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Not applicable Interventional

The SUN Clinical Trial (Safety Utilizing NUsurface Meniscus Implant)

NCT02483988
View directory record Official record
Conditions
Post-Meniscectomy Pain Syndrome, Osteoarthritis, Knee
Interventions
NUsurface® Meniscus Implant
Device
Lead sponsor
Phoenix Kinetics
Industry
Eligibility
30 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • La Mesa, California • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Neonatal Warming to Prevent Hypothermia

NCT04827394
View directory record Official record
Conditions
Hypothermia
Interventions
Neonatal warming mattress, Sterile polyethylene wrap
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 55 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing

NCT01427296
View directory record Official record
Conditions
Colon Cleansing
Interventions
Polyethylene glycol, Oral sodium phosphate solution
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
18
States / cities
San Carlos, California • Bristol, Connecticut • Macon, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

NCT06030297
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Diode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System
Procedure · Drug · Diagnostic Test + 1 more
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 27, 2026, 10:27 PM EDT
Not listed Not applicable Interventional

Umbilical Cord Care for the Prevention of Colonization

NCT01893060
View directory record Official record
Conditions
Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)
Interventions
Povidone-Iodine, Chlorhexidine gluconate, Pluronic Cream, control
Drug · Other
Lead sponsor
University of Virginia
Other
Eligibility
Up to 7 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Sep 27, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Herbal Mouthrinse for Oral Mucositis Study

NCT01898091
View directory record Official record
Conditions
Oral Mucositis
Interventions
Neem Mouthrinse, Placebo Mouthrinse
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 27, 2026, 10:27 PM EDT